Skip to main content
OpenTrials
Completed

NCT Number: NCT00314249

Study of Milnacipran for the Treatment of Fibromyalgia

The purpose of this study was to demonstrate the efficacy and safety of milnacipran at a dosage of 100 mg/day in the treatment of the fibromyalgia syndrome or the pain associate with fibromyalgia.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Forest Investigative Site, Tuscaloosa, Alabama, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • diagnosis of fibromyalgia defined by 1990 American College of Rheumatology (ACR) Criteria

Exclusion criteria

  • psychiatric illness,
  • depression,
  • suicidal risk,
  • substance abuse,
  • pulmonary dysfunction,
  • renal impairment,
  • active cardiac disease,
  • liver disease,
  • autoimmune disease,
  • cancer,
  • inflammatory bowel disease

Treatment and study plan

Placebo

Drug

Placebo, oral administration, twice daily for 12 weeks

Milnacipran 100mg

Drug

Milnacipran 100mg per day (50mg BID [twice a day])

Primary outcomes

  1. Composite Syndrome Responder Status

    Time frame: At the end of the three-month stable dose treatment phase

    Composite Syndrome Responder Status is the number of responders based on 3 domains: (1) 30% reduction in pain (as recorded in the Patient Experience Diary [PED], electronic diary, during the morning report; 24 hour recall); (2) patient global impression of change (PGIC) score of "very much improved" and "much improved;" and (3) physical function improvement of 6 or more points on Short Form-36 Physical Component Summary (SF-36 PCS)

  2. Composite Pain Responder Status

    Time frame: At the end of three-month stable dose treatment phase

    Composite Pain Responder Status is the number of responders based on two domains: (1) 30% reduction in pain (as recorded in the Patient Experience Diary [PED], electronic diary, during the morning report; 24 hour recall); and (2) Patient Global Impression of Change (PGIC) score of "very much improved" or "much improved."

Secondary outcomes

  1. Time-Weighted Average of Patient Experience Diary (PED) Reported Morning 24-Hour Recall Pain Scores for Weeks 1-12 of the Stable Dose Phase

    Time frame: Weeks 1 through 12 of the stable dose treatment phase (Visit TX0-TX12)

    Time-weighted average (area under the curve [AUC]) of the weekly average Patient Experience Diary (PED)-reported morning recall pain scores for weeks 1 through 12 of the stable dose treatment phase is the area under the Patient Experience Diary (PED)-time curve estimated using the trapezoidal method and normalized by time.

    PED is the Patient Experience Diary, an electronic diary system used for collection of patient self-reported pain data. Outcome measure is assessed using the VAS Pain Intensity Scale from 0-100 millimeters anchored at 0 mm (no pain) to 100 mm (worst possible pain).

  2. Time-Weighted Average of Patient Global Impression of Change (PGIC) From Visit TX0-TX12.

    Time frame: Weeks 1-12 (Visit TX0-TX12) of the stable dose treatment phase

    Time-weighted average (area under the curve [AUC]) for Patient Global Impression of Change (PGIC) from Visit TX0-TX12 is the area under the PGIC-time curve estimated using the trapezoidal method and normalized by time.

    PGIC is an efficacy assessment on a scale of 1-7 taken at visits TX0-TX12. The wording of the assessment is as follows: "Since the start of the study, overall my fibromyalgia is:" 1=Very Much Improved, 2=Much Improved, 3=Minimally Improved, 4=No Change, 5=Minimally Worse, 6=Much Worse, and 7-Very Much Worse.

  3. Change From Baseline in the Multi-Dimensional Fatigue Inventory (MFI) Total Score at Visit TX12.

    Time frame: Baseline through end of week 12 (Visit TX12)

    Change from Baseline in the Multi-Dimensional Fatigue Inventory (MFI) total score at TX12. Negative differences indicate decrease of fatigue.

    MFI is a subjective report of fatigue symptoms consisting of 20 items that can be scored to produce 5 dimensions: general fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity. The MFI is a 1-5 scale with 1="yes, that is true" and 5="no, that is not true."

  4. Time-Weighted Average of the Short Form-36 Physical Component Summary (SF-36 PCS) Score From Visit TX0-TX12

    Time frame: Weeks 1-12 (Visit TX0-TX12) of the stable dose treatment phase

    Short Form-36 (SF-36): pt. questionnaire (36 questions) which give rise to 8 domains & 2 component summaries (mental and physical); assessing quality of life, health & functional status.

    SF-36 PCS: weighted summary of physical function using all 8 domains.

    Scores are standardized so that the range for all domains and component summaries is 0 (worst possible score) to 100 (best possible score). Higher scores indicate better health or functional status.

    SF-36 PCS AUC (Area under the Curve): estimated using trapezoidal method, normalized by time.

Sponsors and collaborators

Lead sponsor

Forest Laboratories

Industry

Collaborators

  • Cypress Bioscience, Inc.

Registry information

Official study title

A Phase III Pivotal, Multicenter, Double-blind, Randomized, Placebo-Controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia.

Important dates

Study start
2006
Primary completion
2008
First posted
Apr 13, 2006
Registry last updated
Jan 20, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.